| Zacks Company Profile for Anthera Pharmaceuticals, Inc. (ANTH : OTC) |
|
|
| |
| • Company Description |
| Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj?gren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 288 shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: 1.82 |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
25801 INDUSTRIAL BOULEVARD SUITE B
-
HAYWARD,CA 94545
USA |
ph: 510-856-5600
fax: 510-856-5597 |
None |
http://www.anthera.com |
|
|
| |
| • General Corporate Information |
Officers
Paul F. Truex - Chairman of the Board of Directors
J. Craig Thompson - Chief Executive Officer and Director
May Liu - Senior Vice President; Finance and Administration
Christopher S. Henney - Director
Brian R. Mueller - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03674U300
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 5.00 (0.13:1)
Beta: 1.82
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
